If C is creatinine clearance and E and TR are rates of phosphate excretion and reabsorption, the serum phosphate concentration (P) is the sum of E/C and TR/C, i.e., the amounts of phosphate excreted and reabsorbed per volume of filtrate. At equilibrium, influx of phosphate into plasma determines E, and E/C quantifies the contribution of phosphate influx to P. We used data obtained at 688 clinic visits of 387 patients to analyze the evolution of P in chronic kidney disease (CKD) stages G1 - 5 (dialysis excluded). E/C was calculated as (P×cr)/cr and TR/C as P-E/C (where u is urine, s is serum, and cr is creatinine). Means of these parameters were plotted against CKD stages, and correlations among variables were determined with regression analyses. In comparison to values in CKD stages G1 - 2, E/C rose and TR/C fell by the same amount in CKD G3a and G3b, and P did not change. In stages G4 and G5, E/C increased sharply, TR/C fell minimally, and P rose significantly. At estimated glomerular filtration rate (eGFR) ≥45 mL/min/1.73m, TR/C was the principal determinant of P at eGFR < 45 mL/min/1.73m, contributions of E/C and TR/C to P were comparable. Taken together, our results show that in CKD stages G4 and G5, the effect of phosphate reabsorption on P changes negligibly while that of phosphate influx increases dramatically. Because the tubular response to rising E/C is limited, maintenance of stable P in advanced CKD requires extreme reduction of phosphate influx into plasma. TR/C may define the lowest attainable P.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.5414/CN111260 | DOI Listing |
Can J Kidney Health Dis
January 2025
Can Tho University of Medicine and Pharmacy, Can Tho, Vietnam.
Objectives: Chronic kidney disease (CKD) is associated with disability, low quality of life, and mortality. However, most cases are asymptomatic, often detected incidentally, or only recognized when they have progressed to the later stages with complications. The present study aimed to determine the prevalence of CKD and develop a predictive nomogram for CKD in Vietnamese adults.
View Article and Find Full Text PDFNephrology (Carlton)
January 2025
Faculty of Medicine, Dentistry & Health Sciences Melbourne, The University of Melbourne, Melbourne, Victoria, Australia.
Chronic kidney disease is characterised by the progressive loss of kidney function. However, predicting who will progress to kidney failure is difficult. Artificial Intelligence, including Machine Learning, shows promise in this area.
View Article and Find Full Text PDFClin Pharmacokinet
January 2025
Inria-Inserm COMPO Team, Centre Inria Sophia Antipolis-Méditerranée, CRCM, Inserm U1068-CNRS UMR7258-Aix-Marseille University UM105, Marseille, France.
Background: Cefotaxime is a widely prescribed cephalosporin antibiotic used to treat various infections. It is mainly eliminated unchanged by the kidney through tubular secretion and glomerular filtration. Therefore, a reduction of kidney function may increase exposure to the drug and induce toxic side effects.
View Article and Find Full Text PDFAm J Physiol Cell Physiol
January 2025
Department of Physiology and Pathophysiology, School of Basic Medical Sciences, State Key Laboratory of Vascular Homeostasis and Remodeling, Peking University, Beijing 100191, China.
Arterial stiffening is a hallmark of chronic kidney disease (CKD) related cardiovascular events and is primarily attributed to the elevated matrix stiffness. Stiffened arteries are accompanied by low-grade inflammation, but the causal effects of matrix stiffness on inflammation remain unknown. For analysis of the relationship between arterial stiffness and vascular inflammation, pulse wave velocity (PWV) and aortic inflammatory markers were analyzed in an adenine-induced mouse model of CKD in chronological order.
View Article and Find Full Text PDFInt J Bipolar Disord
January 2025
Department of Nephrology, Jeroen Bosch Ziekenhuis, 's-Hertogenbosch, The Netherlands.
Background: A surrogate marker (a substitute indicator of the true outcome) is needed to predict subgroups of long-term lithium users at risk of end-stage kidney disease (ESKD). In this narrative review the aim is to determine the optimal surrogate endpoint for ESKD in long-term lithium users in a scientific context. MAIN: In a literature search in long-term lithium users, no studies on surrogate measurements on ESKD were identified.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!